POY_1170x120_8-12-19

Health care executive Ty Burgess launches One CBD

Print Friendly, PDF & Email

DALLAS  — With an estimated 2 million people in the United States living with a substance-use disorder related to prescription opioid pain medication, ex-hospital chief executive officer, Ty Burgess is on a mission to decrease that number. Burgess understands the issue well, having a history of debilitating health conditions, including autoimmune disease and chronic pain that led to himself being dependent on opioid medications for several years. After juggling up to 15 different prescriptions, he began searching for a better way. This led to the creation of One CBD and with it… a story of hope and healing.

“I knew those seemingly endless days of pain were destined to serve a purpose,” said Burgess. “As the pain got worse and my prescription count increased, I found myself in a very dark place. This is the point where curiosity led to questions, and questions led to alternative approaches. With skepticism aside, I began to research. The results unveiled the fact that prescriptions were no longer needed, and in the process, I began to develop a passion for natural healing. One so strong that it compelled me to leave my career in traditional health care of almost 20 years to create this company.”

One CBD delivers a unique approach to modern mindful wellness, backed with medical expertise and science-based research. With the goal of promoting overall wellness, One CBD offers more than 14 different naturally-balancing products, all of which are from 100% organically farmed hemp, GMO-free, THC-free, 3rd-party lab tested, sourced from US farmers and compliant with Good Manufacturing Practices (GMP).

At the heart of One CBD is giving back. One CBD will donate 1% of every sale to organizations that support initiatives such as opioid addiction, holistic wellness and ecological sustainability. Look for announcements throughout the year on new charities being sponsored and supported.

 


EMC_728x90

CURA_728x90_8-22-19

Comments are closed.